Novel strategies for
pharmacotherapy of depression
by
Maubach KA, Rupniak NM, Kramer MS,
Hill RG Merck Sharp & Dohme
Neuroscience Research Centre Terlings Park,
Eastwick Road, Harlow, Essex, CM20 2QR, UK.
karen_maubach@merck.com
Curr Opin Chem Biol 1999 Aug; 3(4): 481-8

ABSTRACT

Modulating monoamine activity as a therapeutic strategy continues to dominate antidepressant research, with a recent emphasis on agents with multiple targets, including combined serotonin/noradrenaline re-uptake inhibitors and numerous serotonin receptor ligands. An important new development has been the emergence of potential novel mechanisms of action, notably modulation of the activity of neuropeptides substance P and corticotrophin-releasing factor, and the intracellular messenger cyclic adenosine monophosphate. Efforts in this area have recently been rewarded by the demonstration of antidepressant efficacy of the substance P receptor antagonist MK-0869.

cAMP
SAMe
DHEA
Inositol
YKP10A
Antisense
Hypericum
21st Century
Pregnenolone
Buprenorphine
Neuropeptide-Y
NMDA antagonists
New antidepressants
Enkephalinase inhibitors
Substance P antagonists
Neurokinins/substance P
Old and new antidepressants
New substance P antagonists
Nitric oxide synthase inhibitors
Antidepressants and new brain cells
Mood enhancement via stem cell therapy

Refs
and further reading

HOME
HedWeb
Nootropics
Cocaine.org
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family